# A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

> **NCT04432207** · PHASE1 · TERMINATED · sponsor: **Imugene Limited** · enrollment: 24 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Stage IIIB
- Non-small Cell Lung Cancer Stage IV
- Squamous Non-small-cell Lung Cancer
- Large Cell Carcinoma Lung
- Adenocarcinoma Lung

## Interventions

- **BIOLOGICAL:** IMU-201 (administered as PD1-Vaxx) - Regimen 1
- **BIOLOGICAL:** IMU-201 (administered as PD1-Vaxx) - Regimen 2
- **BIOLOGICAL:** IMU-201 (administered as PD1-Vaxx) - Regimen 3
- **DRUG:** Atezolizumab
- **DRUG:** Standard of care chemotherapy

## Key facts

- **NCT ID:** NCT04432207
- **Lead sponsor:** Imugene Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-30
- **Primary completion:** 2024-10-08
- **Final completion:** 2024-11-07
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Portfolio prioritization
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04432207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04432207, "A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04432207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*